Asia Healthcare Industry Digest
SEE OTHER BRANDS

The latest healthcare and wellness news from Asia and the Pacific

Asia Healthcare Industry Digest: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Asia Healthcare Industry Digest.

Press releases published on May 19, 2025

Philips launches real-time 3D intracardiac imaging in Europe, expanding access to minimally invasive heart procedures

Philips launches real-time 3D intracardiac imaging in Europe, expanding access to minimally invasive heart procedures

May 19, 2025 VeriSight Pro 3D ICE catheter is a pioneering innovation — a miniaturized ultrasound probe embedded at the tip of a thin, steerable catheter, navigated through the vascular system into the heart chambers to deliver high-quality 2D and 3D …

LIfT BioSciences presents latest data on its first-in-class Immunomodulatory Alpha Neutrophils at International Society for Cell and Gene Therapy

LIfT BioSciences presents latest data on its first-in-class Immunomodulatory Alpha Neutrophils at International Society for Cell and Gene Therapy

LIfT BioSciences presents latest data on its first-in-class Immunomodulatory Alpha Neutrophils at International Society for Cell and Gene Therapy London, 19 May 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global …

AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041, adding one more indication with long term intellectual property protection

AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041, adding one more indication with long term intellectual property protection

PRESS RELEASE AB SCIENCE RECEIVES CHINESE PATENT PROTECTING MASITINIB IN THE TREATMENT OF COVID-19 UNTIL 2041, ADDING ONE MORE INDICATION WITH LONG TERM INTELLECTUAL PROPERTY PROTECTION Paris, May 19, 2025, 8am CET AB Science SA (Euronext - FR0010557264 - …

AB Science reçoit un brevet chinois protégeant le masitinib dans le traitement du Covid-19 jusqu’en 2041, ajoutant ainsi une indication supplémentaire bénéficiant d’une protection à long terme de la propriété intellectuelle

AB Science reçoit un brevet chinois protégeant le masitinib dans le traitement du Covid-19 jusqu’en 2041, ajoutant ainsi une indication supplémentaire bénéficiant d’une protection à long terme de la propriété intellectuelle

COMMUNIQUÉ DE PRESSE AB SCIENCE REÇOIT UN BREVET CHINOIS PROTÉGEANT LE MASITINIB DANS LE TRAITEMENT DU COVID-19 JUSQU'EN 2041, AJOUTANT AINSI UNE INDICATION SUPPLÉMENTAIRE BÉNÉFICIANT D'UNE PROTECTION À LONG TERME DE LA PROPRIÉTÉ INTELLECTUELLE Paris, 19 …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service